Since Leqembi was approved in the U.S. in the summer of 2023, controversy has roiled among clinicians over whether the Alzheimer’s anti-amyloid drug’s risks…
At the 2024 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Madrid, Spain, scientists and drug development companies gathered to report on recent successes…
On October 23nd, the UK’s drug regulation agency — UK Medicines and Healthcare products Regulatory Agency — approved Eli Lilly’s anti-amyloid drug Kisunla for…
In just a single year of studying a rare genetic mutation in a single family in the Arctic reaches of remote northern Sweden, a…
The new monoclonal anti-amyloid Alzheimer’s drugs are a constant source of controversy among doctors, insurers, and regulators worldwide. One of this buzzy new drug class,…
On September 26th, Cassava Sciences’ founder and former CEO Remi Barbier, as well as former vice president Lindsay Burns agreed to pay the Securities…
While the world tracks the progress of disease-modifying Alzheimer’s anti-amyloids through the drug development and FDA approval pipeline, there are symptomatic treatments making their…
No one can tell for certain if you’ll develop Alzheimer’s disease 10, 20 or 30 years from now — but you can certainly lower…
Getting an accurate Alzheimer’s diagnosis can take years — and several visits to the doctor. After taking a medical history, neurological exam, and blood tests…
According to legend, Kaldi, an Ethiopian goat herder who lived more than 1000 years ago, noticed something curious about his goats: If they ate…
Have you made that free flu shot appointment at your local pharmacy yet? The data shows that people who skip their flu shot had…
More than one billion adults worldwide have high blood pressure, but since it doesn’t often cause symptoms, half of them don’t even know they…
Maybe you’ve heard of amyloid plaques, which build up in the brains of people with Alzheimer’s. But there’s another protein biomarker in the mix:…
Athira Pharma’s experimental Alzheimer’s drug fosgonimeton hit a speedbump on its way toward FDA approval: The treatment failed to show a clinical benefit in…
In February, Biogen announced it was pulling Aduhelm off the market. The company will continue supplying the drug until November but stopped providing it…